Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04598269 · ClinicalTrials.gov registry record · Phase 2
Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis
A Phase 2 study of Atopic Dermatitis, sponsored by Aclaris Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 14
- Study locations
NCT04598269 is a Phase 2 study of Atopic Dermatitis that has completed, run by Aclaris Therapeutics. The registered enrollment target is 50 participants, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (92% lower). The trial reports 14 study locations across 11 states.
The verdict
NCT04598269, a Phase 2 study of Atopic Dermatitis, has completed, sponsored by Aclaris Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 14
- Study locations
Study Summary
This is a first-in-human, randomized, double-blind, parallel-group, vehicle-controlled study to evaluate the efficacy, safety, tolerability, and PK of ATI-1777 solution following twice-daily applications to target areas of participants with moderate or severe atopic dermatitis (AD).
Conditions Studied
Interventions
- DRUG Vehicle
- DRUG ATI-1777
Study Locations (14)
California
- Aclaris Investigational Site - Encino
- Aclaris Investigational Site - Los Angeles
Texas
- Aclaris Investigational Site - Austin
- Aclaris Investigational Site - San Antonio
Virginia
- Aclaris Investigational Site - Lynchburg
- Aclaris Investigational Site - Newport News
Arizona
- Aclaris Investigational Site - Scottsdale
Florida
- Aclaris Investigational Site - Tampa
Indiana
- Aclaris Investigational Site - Indianapolis
Kansas
- Aclaris Investigational Site - Overland Park
Nebraska
- Aclaris Investigational Site - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2020-09-30 |
| Est. Completion | 2021-04-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04598269
The ClinicalTrials.gov registry entry for NCT04598269 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (92% lower). The listed sponsor is Aclaris Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Vehicle is the first listed.
NCT04598269 reports 14 study locations spanning 11 distinct geographic areas - top geographies include California, Texas, Virginia.
Frequently Asked Questions
What is clinical trial NCT04598269 about?
NCT04598269 is a clinical study titled "Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis". This is a first-in-human, randomized, double-blind, parallel-group, vehicle-controlled study to evaluate the efficacy, safety, tolerability, and PK of ATI-1777 solution following twice-daily applications to target areas of participants with moderate or severe atopic dermatitis (AD).
What is the current status of trial NCT04598269?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2020-09-30. Estimated completion is 2021-04-22.
What conditions does trial NCT04598269 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT04598269?
The interventions under investigation include: Vehicle (DRUG), ATI-1777 (DRUG).
Who is sponsoring clinical trial NCT04598269?
This trial is sponsored by Aclaris Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04598269 being conducted?
This trial has 14 study locations across Arizona, California, Florida, Indiana, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Cardamom and Topical Roseomonas in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
A Study Evaluating TRIV-509 in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.